The combination of a significant EPS miss, widening losses, workforce reduction, and C-suite departures signals operational distress despite the Phase 3 enrollment milestone. Traders should watch for potential dilution risk given the cash burn rate ($79.3M net loss in H1 2026) and the extended runway into 1H 2029, which may require future capital raises. The NMIBC program deprioritization removes a pipeline catalyst, making the stock dependent solely on ocular oncology data readouts in 2H 2027.
Price Chart
Executive Summary
Aura Biosciences reported Q2 2026 EPS of -$0.48, a 33.3% miss vs consensus of -$0.38, with revenue of $0. The net loss widened to $45.6M from $27.0M in Q2 2025, driven by increased R&D and G&A expenses including $10.3M in stock-based compensation from executive transitions. The company announced a 20% workforce reduction and leadership departures (CFO, CLO, CTO) to focus on ocular oncology, extending cash runway into 1H 2029, while the Phase 3 CoMpass trial remains fully enrolled with topline data expected in 2H 2027.
Key Financial Metrics
Key Facts
- Q2 2026 EPS -$0.48 vs consensus -$0.38 (33.3% miss)
- Net loss widened to $45.6M from $27.0M in Q2 2025
- R&D expenses increased to $30.7M from $22.9M; G&A surged to $17.3M from $5.7M, including $10.3M stock-based compensation
- 20% workforce reduction and restructuring charges of $2.9M-$3.2M
- CFO, CLO, and CTO stepping down; new COO, Chief Regulatory and Quality Officer, and Chief People Officer appointed
- Phase 3 CoMpass trial fully enrolled with 108 patients; topline data expected 2H 2027
- Cash and marketable securities $323.8M; cash runway extended into 1H 2029
- NMIBC program deprioritized to focus on ocular oncology
Financial Impact
Net loss of $45.6M in Q2 2026, 69% wider than $27.0M in Q2 2025; restructuring charges of $2.9M-$3.2M
Risk Factors
- Cash burn rate of ~$40M/quarter may necessitate dilutive financing before 1H 2029
- Phase 3 CoMpass trial failure would eliminate the primary pipeline value
- Leadership turnover could disrupt execution of ocular oncology strategy
- NMIBC program deprioritization reduces pipeline optionality
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3342543 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 5w ago | Institutional Cluster | $6.45 $6.56 | ▲ +1.71% | ▲ +2.27% | $6.30 (−2.33%) |
Aug 21, 2026 9w ago | EFFECT | $7.80 $6.36 | ▲ +18.46% | ▲ +17.94% | $6.30 (+19.23%) |
Aug 11, 2026 11w ago | 8-K | $8.04 $7.20 | ▲ +10.45% | ▲ +9.39% | $6.30 (+21.64%) |
Aug 11, 2026 11w ago | Press Release | $8.04 $7.20 | ▲ +10.45% | ▲ +9.39% | $6.30 (+21.64%) |
Jul 8, 2026 15w ago | 8-K | $7.25 $7.18 | ▼ −0.97% | ▼ −4.24% | $6.30 (−13.10%) |
May 19, 2026 23w ago | Press Release | $7.47 $6.34 | ▼ −15.13% | ▼ −15.87% | $6.30 (−15.66%) |
May 5, 2026 24w ago | 8-K | $8.29 $6.88 | ▲ +17.01% | ▲ +19.79% | $6.30 (+24.00%) |
May 5, 2026 24w ago | Press Release | $8.29 $6.88 | ▲ +17.01% | ▲ +19.79% | $6.30 (+24.00%) |
May 4, 2026 25w ago | 8-K | $8.90 $6.90 | ▼ −22.47% | ▼ −27.43% | $6.30 (−29.21%) |
May 4, 2026 25w ago | Press Release | $8.35 $7.19 | ▲ +13.89% | ▲ +19.54% | $6.30 (+24.55%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers